Cover Image
市場調查報告書

溴結構域蛋白4:開發中產品分析

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 371018
出版日期 內容資訊 英文 113 Pages
訂單完成後即時交付
價格
Back to Top
溴結構域蛋白4:開發中產品分析 Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Pipeline Review, H1 2017
出版日期: 2017年06月20日 內容資訊: 英文 113 Pages
簡介

本報告提供以溴結構域蛋白4為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

溴結構域蛋白4 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Aptose Biosciences Inc.
  • Arvinas, Inc.
  • C4 Therapeutics, Inc.
  • Constellation Pharmaceuticals, Inc.
  • ConverGene, LLC
  • 第一三共
  • Dybly AG
  • F. Hoffmann-La Roche Ltd.
  • Incyte Corporation
  • Kainos Medicine, Inc.
  • Merck & Co., Inc.
  • Resverlogix Corp.
  • Trillium Therapeutics Inc.
  • Zenith Epigenetics Corp

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0874TDB

Summary

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) pipeline Target constitutes close to 39 molecules. Out of which approximately 32 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 4 - Pipeline Review, H1 2017, outlays comprehensive information on the Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Bromodomain-containing protein 4 is a protein encoded by the BRD4 gene. It plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. It promotes phosphorylation of Ser-2 of the C-terminal domain (CTD) of RNA polymerase II. It acts as a regulator of p53/TP53-mediated transcription. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5, 21 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 5 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular, Central Nervous System, Genito Urinary System And Sex Hormones, Metabolic Disorders, Genetic Disorders, Ophthalmology and Respiratory which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Solid Tumor, Multiple Myeloma (Kahler Disease), Breast Cancer, Myelodysplastic Syndrome, Diffuse Large B-Cell Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Hematological Tumor, Inflammation, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Ovarian Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Atherosclerosis, Colorectal Cancer, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Non-Small Cell Lung Cancer, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Alzheimer's Disease, B-Cell Non-Hodgkin Lymphoma, Blood Cancer, Burkitt Lymphoma, Carcinomas, Chronic Kidney Disease (Chronic Renal Failure), Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Coronary Artery Disease (CAD) (Ischemic Heart Disease), Fabry Disease, Follicular Lymphoma, Glioblastoma Multiforme (GBM), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Hypercholesterolemia, Idiopathic Pulmonary Fibrosis, Lung Cancer, Malignant Pleural Mesothelioma, Melanoma, Metastatic Brain Tumor, Metastatic Liver Cancer, Nephropathy, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Pre-Diabetes/Impaired Glucose Tolerance, Renal Cell Carcinoma, Retinal Degeneration, Rheumatoid Arthritis, Small-Cell Lung Cancer, Substance (Drug) Abuse and Systemic Lupus Erythematosus.

Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
  • The report reviews Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Overview
    • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Companies Involved in Therapeutics Development
    • Aptose Biosciences Inc
    • Arvinas Inc
    • AstraZeneca Plc
    • ConverGene LLC
    • Dybly AG
    • F. Hoffmann-La Roche Ltd
    • Forma Therapeutics Inc
    • GlaxoSmithKline Plc
    • Incyte Corp
    • Kainos Medicine Inc
    • Merck & Co Inc
    • Nuevolution AB
    • Plexxikon Inc
    • Resverlogix Corp
    • Trillium Therapeutics Inc
  • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Drug Profiles
    • apabetalone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARCC-29 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARV-763 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARV-771 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARV-825 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AZD-5153 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • birabresib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-223 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CG-250 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CK-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPI-0610 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DCBD-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DYB-186 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EP-11313 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FT-1101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-525762 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INCB-54329 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KM-601 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MA-2014 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MS-417 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MZ-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEO-2734 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NUE-7770 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PLX-51107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-6146 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RVX-2135 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SF-2523 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SF-2535 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit Bromodomain Containing Protein-4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit BRD4 and HDAC1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit BRD4 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit BRD4 for Ovarian Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRX-3177 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TTI-281 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZBC-260 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZEN-3694 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Dormant Products
  • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Discontinued Products
  • Bromodomain Containing Protein 4 (Protein HUNK1 or BRD4) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 05, 2017: Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017
      • Jun 05, 2017: Zenith Announces Issuance of Patent for ZEN-3694 and Presentation Details at BIO International Convention
      • May 31, 2017: Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain
      • May 30, 2017: Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
      • May 23, 2017: Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success
      • May 15, 2017: Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial
      • May 01, 2017: SignalRx Discloses its Novel Immuno-Oncology Program Approach at the 12th Annual Drug Discovery Chemistry 2017 Meeting
      • Apr 25, 2017: SignalRx to Present at the 12th Annual Drug Discovery Chemistry 2017 Meeting on its First-In-Class Triple PI3K/CDK4-6/BRD4 Inhibitor SRX3177 for Treating Cancer
      • Apr 03, 2017: SignalRx to Present at the AACR Annual Meeting on its First-In-Class Triple PI3K/CDK4-6/BRD4 Inhibitor SRX3177 for Treating Cancer
      • Mar 17, 2017: Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities
      • Mar 15, 2017: Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
      • Feb 23, 2017: Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial
      • Feb 13, 2017: Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy and Neurodegenerative Eye Disease
      • Feb 01, 2017: SignalRx Pharmaceuticals Announces Breakthrough Results on Novel Anti-Cancer Dual PI3K-BRD4 Inhibition Paradigm in PNAS Publication
      • Jan 23, 2017: Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Indications, H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Indications, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1)
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Investigation by Universities/Institutes, H1 2017
  • Products under Investigation by Universities/Institutes, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pipeline by Aptose Biosciences Inc, H1 2017
  • Pipeline by Arvinas Inc, H1 2017
  • Pipeline by AstraZeneca Plc, H1 2017
  • Pipeline by ConverGene LLC, H1 2017
  • Pipeline by Dybly AG, H1 2017
  • Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Pipeline by Forma Therapeutics Inc, H1 2017
  • Pipeline by GlaxoSmithKline Plc, H1 2017
  • Pipeline by Incyte Corp, H1 2017
  • Pipeline by Kainos Medicine Inc, H1 2017
  • Pipeline by Merck & Co Inc, H1 2017
  • Pipeline by Nuevolution AB, H1 2017
  • Pipeline by Plexxikon Inc, H1 2017
  • Pipeline by Resverlogix Corp, H1 2017
  • Pipeline by Trillium Therapeutics Inc, H1 2017
  • Dormant Projects, H1 2017
  • Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development by Stage of Development, H1 2017
  • Number of Products under Development by Therapy Areas, H1 2017
  • Number of Products under Development by Top 10 Indications, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
Back to Top